Lilly study shows long-term benefits of Taltz for psoriatic arthritis

Lilly has announced the findings of a clinical trial that demonstrates the long-term effectiveness of the drug Taltz in the treatment of psoriatic arthritis.

Interim results from the extension period of the phase III SPIRIT-P2 study have been presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting, showing the prolonged benefits Taltz offers over a 52-week period.

Patients with active psoriatic arthritis treated with Taltz who were previously intolerant or had inadequate responses to TNF inhibitor therapies were able to experience improvements in the signs and symptoms of their disease for up to a year.

The majority of patients treated with Taltz achieved at least a 20 percent improvement in disease activity, thus meeting the primary endpoint trial. Subjects also maintained improvements in key secondary endpoints such as skin clearance and physical function.

Dr Lotus Mallbris, vice-president and immunology platform team leader at Lilly Bio-Medicines, said: "This data is promising for the more than 37 million people worldwide who suffer from joint and skin symptoms of psoriatic arthritis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.